Tweets
Breakthrough COVID-19 in rheum pts: great data @rheum_covid
B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others
Booster (& booster booster) vaccine doses + other mitigation badly needed!
@rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
#Depression is associated with a 3x increased mortality risk in patients with incident #RA.
👉🏼Results from #DANBIO
👉🏼~11000 RA pts, ~1000 starting antidepressants
Abs#1659 #ACR21 @RheumNow
https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
Richard Conway @RichardPAConway ( View Tweet )
4 years 8 months ago
#ACR21 L04 @rheumcat on #COVID19 in vaxed pts
▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts
⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%).
@RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
You need to visit this nonprofit on the #ACR21 website and also their website https://t.co/8SrCHZUrk0
to help patients & doctors navigate getting the meds pts need. There are resources explaining step therapy and how to navigate access restrictions for patients. @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 8 months ago
No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i
⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD
⭐️no specific clustering noted
Abs#1782
#ACR21 @RheumNow
https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo
Links:
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 8 months ago
Dr Kwok on isolated axial disease in PsA. Seen in 2% of cohort. Significantly more likely to be HLA-B27 positive. Lower HAQ score. No obvious predictors of future development of peripheral disease. Abstr#1775 #ACR21 @RheumNow https://t.co/SqpaLjCrmm
Richard Conway @RichardPAConway ( View Tweet )
4 years 8 months ago
#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout
⭐️Effectively brought down serum uric acid <5, dose-dependent
⭐️10% pts gout flare with urate lowering
@Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
Minority (African American and Hispanic) #SLE patients have worse #COVID19 outcomes – double whammy! Data from the @rheum_covid #ACR21 @rheumnow #abst1933
Bella Mehta @bella_mehta ( View Tweet )
4 years 8 months ago
#ACR21 L07 - Rx for IBM?!
⭐️Depletion of KLRG1+ T cells - trial of ABC008
⭐️Presented data from 3 patients in 1st human studies
▶️single SC 0.1 mg/kg dose depletes CD8+KLRG1+ cells wo safety concerns
@Rheumnow https://t.co/1J8PrOqbWh
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation
Now there hope might be on the horizon
Exciting to see the science & a feasible target
#ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80
Dr. Antoni Chan @synovialjoints ( View Tweet )
4 years 8 months ago
